Real-World Effectiveness and Safety of Nemolizumab in Moderate-to-Severe Atopic Dermatitis: A Phase IV, Prospective, Non-Interventional Study Design From RE-UNITE-AD (NCT06988605). J of Skin 2026, 10 (2), s746. https://doi.org/10.25251/nq0ynj58.